Olema Pharmaceuticals, Inc. Financials
This page shows Olema Pharmaceuticals, Inc. (OLMA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Olema Pharmaceuticals, Inc. passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Olema Pharmaceuticals, Inc. generates $0.81 in operating cash flow (-$104.4M OCF vs -$129.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Olema Pharmaceuticals, Inc.'s EBITDA was -$141.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 35.6% from the prior year.
Olema Pharmaceuticals, Inc. generated -$104.5M in free cash flow in fiscal year 2024, representing cash available after capex.
Olema Pharmaceuticals, Inc. reported -$129.5M in net income in fiscal year 2024. This represents a decrease of 34.0% from the prior year.
Olema Pharmaceuticals, Inc. earned $-2.20 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 2.8% from the prior year.
Olema Pharmaceuticals, Inc. held $139.5M in cash against $0 in long-term debt as of fiscal year 2024.
Olema Pharmaceuticals, Inc. had 74M shares outstanding in fiscal year 2024. This represents an increase of 35.1% from the prior year.
Olema Pharmaceuticals, Inc. invested $124.5M in research and development in fiscal year 2024. This represents an increase of 44.6% from the prior year.
Olema Pharmaceuticals, Inc. invested $159K in capex in fiscal year 2024, funding long-term assets and infrastructure.
OLMA Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $40.0M-9.0% | $43.9M+43.4% | $30.6M | N/A | $33.2M+14.1% | $29.1M-2.6% | $29.9M | N/A |
| SG&A Expenses | $5.9M+49.6% | $4.0M-6.8% | $4.2M | N/A | $4.4M-0.6% | $4.4M-0.8% | $4.5M | N/A |
| Operating Income | -$45.9M+4.2% | -$47.9M-37.3% | -$34.9M | N/A | -$37.6M-12.2% | -$33.5M+2.4% | -$34.3M | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$42.2M+3.6% | -$43.8M-44.1% | -$30.4M | N/A | -$34.6M-13.7% | -$30.4M+1.9% | -$31.0M | N/A |
| EPS (Diluted) | $-0.49+3.9% | $-0.51-41.7% | $-0.36 | N/A | $-0.60-11.1% | $-0.54+3.6% | $-0.56 | N/A |
OLMA Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $352.5M-7.7% | $382.0M-6.7% | $409.6M-9.2% | $451.0M+95.9% | $230.2M-9.6% | $254.6M-3.5% | $263.7M-4.8% | $276.9M |
| Current Assets | $334.3M-9.1% | $367.7M-7.3% | $396.7M-9.5% | $438.5M+101.1% | $218.0M-10.0% | $242.2M-3.9% | $252.1M-5.4% | $266.5M |
| Cash & Equivalents | $35.3M-32.8% | $52.5M+3.6% | $50.6M-63.7% | $139.5M+288.7% | $35.9M+112.5% | $16.9M-49.9% | $33.7M-50.8% | $68.5M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $45.0M+22.3% | $36.8M+40.4% | $26.2M-37.7% | $42.0M+34.4% | $31.3M+14.1% | $27.4M+0.1% | $27.4M+18.8% | $23.1M |
| Current Liabilities | $41.7M+25.6% | $33.2M+27.2% | $26.1M-37.6% | $41.8M+36.0% | $30.7M+15.7% | $26.5M+1.2% | $26.2M+21.3% | $21.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $307.5M-10.9% | $345.2M-10.0% | $383.5M-6.2% | $409.0M+105.6% | $198.9M-12.4% | $227.2M-3.9% | $236.3M-6.9% | $253.9M |
| Retained Earnings | -$551.5M-8.3% | -$509.3M-9.4% | -$465.5M-7.0% | -$435.1M-8.4% | -$401.5M-9.4% | -$367.0M-9.0% | -$336.6M-10.1% | -$305.6M |
OLMA Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$34.5M-15.5% | -$29.9M+32.1% | -$44.0M-67.3% | -$26.3M+2.7% | -$27.0M+2.0% | -$27.6M-17.3% | -$23.5M-27.2% | -$18.5M |
| Capital Expenditures | $0 | N/A | N/A | $0 | $0-100.0% | $6K-96.1% | $153K | N/A |
| Free Cash Flow | -$34.5M | N/A | N/A | -$26.3M+2.7% | -$27.0M+2.0% | -$27.6M-16.5% | -$23.6M | N/A |
| Investing Cash Flow | $17.3M-49.5% | $34.2M+175.9% | -$45.1M+60.6% | -$114.4M-349.2% | $45.9M+1041.4% | -$4.9M+75.8% | -$20.1M+34.8% | -$30.9M |
| Financing Cash Flow | $41K+101.6% | -$2.5M-1234.2% | $222K-99.9% | $244.3M+265443.5% | $92K-99.4% | $15.6M+76.9% | $8.8M+1586.6% | $523K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
OLMA Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -12.0%-0.5pp | -11.5%-4.0pp | -7.4% | N/A | -15.0%-3.1pp | -11.9%-0.2pp | -11.7% | N/A |
| Current Ratio | 8.03-3.1 | 11.09-4.1 | 15.22+4.7 | 10.50+3.4 | 7.10-2.0 | 9.13-0.5 | 9.61-2.7 | 12.33 |
| Debt-to-Equity | 0.15+0.0 | 0.11+0.0 | 0.07-0.0 | 0.10-0.1 | 0.16+0.0 | 0.120.0 | 0.12+0.0 | 0.09 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Olema Pharmaceuticals, Inc. profitable?
No, Olema Pharmaceuticals, Inc. (OLMA) reported a net income of -$129.5M in fiscal year 2024.
What is Olema Pharmaceuticals, Inc.'s earnings per share (EPS)?
Olema Pharmaceuticals, Inc. (OLMA) reported diluted earnings per share of $-2.20 for fiscal year 2024. This represents a -2.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Olema Pharmaceuticals, Inc.'s EBITDA?
Olema Pharmaceuticals, Inc. (OLMA) had EBITDA of -$141.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Olema Pharmaceuticals, Inc.'s free cash flow?
Olema Pharmaceuticals, Inc. (OLMA) generated -$104.5M in free cash flow during fiscal year 2024. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Olema Pharmaceuticals, Inc.'s operating cash flow?
Olema Pharmaceuticals, Inc. (OLMA) generated -$104.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Olema Pharmaceuticals, Inc.'s total assets?
Olema Pharmaceuticals, Inc. (OLMA) had $451.0M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Olema Pharmaceuticals, Inc.'s capital expenditures?
Olema Pharmaceuticals, Inc. (OLMA) invested $159K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Olema Pharmaceuticals, Inc. spend on research and development?
Olema Pharmaceuticals, Inc. (OLMA) invested $124.5M in research and development during fiscal year 2024.
How many shares does Olema Pharmaceuticals, Inc. have outstanding?
Olema Pharmaceuticals, Inc. (OLMA) had 74M shares outstanding as of fiscal year 2024.
What is Olema Pharmaceuticals, Inc.'s current ratio?
Olema Pharmaceuticals, Inc. (OLMA) had a current ratio of 10.50 as of fiscal year 2024, which is generally considered healthy.
What is Olema Pharmaceuticals, Inc.'s debt-to-equity ratio?
Olema Pharmaceuticals, Inc. (OLMA) had a debt-to-equity ratio of 0.10 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Olema Pharmaceuticals, Inc.'s return on assets (ROA)?
Olema Pharmaceuticals, Inc. (OLMA) had a return on assets of -28.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Olema Pharmaceuticals, Inc.'s cash runway?
Based on fiscal year 2024 data, Olema Pharmaceuticals, Inc. (OLMA) had $139.5M in cash against an annual operating cash burn of $104.4M. This gives an estimated cash runway of approximately 16 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Olema Pharmaceuticals, Inc.'s Piotroski F-Score?
Olema Pharmaceuticals, Inc. (OLMA) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Olema Pharmaceuticals, Inc.'s earnings high quality?
Olema Pharmaceuticals, Inc. (OLMA) has an earnings quality ratio of 0.81x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.